^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Norepinephrine reuptake inhibitor

    Related drugs:
    1d
    NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab (clinicaltrials.gov)
    P2, N=118, Not yet recruiting, New Approaches to Neuroblastoma Therapy Consortium
    New P2 trial
    |
    Zolinza (vorinostat) • Unituxin (dinutuximab) • Azedra (iobenguane I 131)
    3d
    Vyvanse in Children Aged 6 to 12 Years (clinicaltrials.gov)
    P1, N=40, Recruiting, University of Minnesota | Trial completion date: Nov 2029 --> Jul 2027 | Trial primary completion date: Nov 2028 --> Jul 2026
    Trial completion date • Trial primary completion date
    3d
    Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea (clinicaltrials.gov)
    P4, N=45, Completed, China Medical University Hospital | Recruiting --> Completed | N=132 --> 45
    Trial completion • Enrollment change
    3d
    Duloxetine for LBP (clinicaltrials.gov)
    P4, N=120, Recruiting, Montefiore Medical Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    5d
    Characterization and Prognostic Impact of Fascin Expression in the Tumor Microenvironment of Triple-Negative Breast Cancer: Clues for a Tailored Therapy. (PubMed, Lab Invest)
    These findings highlight the dual role of fascin in tumor cells and the tumor microenvironment (TME), and reinforce its potential as a biomarker for personalized TNBC therapies. Ongoing clinical trials, including HITCLIF, are exploring the efficacy of imipramine in patients with fascin-overexpressing cancers, paving the way for targeted treatment strategies.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • FSCN1 (Fascin Actin-Bundling Protein 1)
    |
    HER-2 expression
    |
    imipramine
    6d
    A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels (clinicaltrials.gov)
    P1, N=174, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc.
    New P1 trial
    7d
    CONCORD: Combination of Novel Therapies for CKD Comorbid Depression (clinicaltrials.gov)
    P2, N=201, Recruiting, Stony Brook University | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    15d
    Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans (clinicaltrials.gov)
    P1, N=122, Completed, University of Zurich | Recruiting --> Completed | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Apr 2025 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    17d
    Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (clinicaltrials.gov)
    P3, N=44, Recruiting, Tanta University | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    17d
    The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia (clinicaltrials.gov)
    P=N/A, N=384, Recruiting, Beijing Tiantan Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    17d
    The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, Beijing Tiantan Hospital
    New trial
    18d
    Methylphenidate in Childhood Apraxia of Speech (clinicaltrials.gov)
    P2, N=18, Completed, Murdoch Childrens Research Institute | Active, not recruiting --> Completed
    Trial completion